• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Recurrent pulmonary lymphangitis carcinomatosis detected on Lu-PSMA-617 post-therapy scan in mCRPC with negative PSMA PET and HRCT.

作者信息

Aggarwal Piyush, Satapathy Swayamjeet, Sood Ashwani, Singh Parneet, Singh Harmandeep, Chopra Sejal, Prakash Gaurav, Mittal Bhagwant Rai

机构信息

Department of Nuclear Medicine, Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, 160012, India.

Department of Clinical Hematology and Medical Oncology, Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, 160012, India.

出版信息

Eur J Nucl Med Mol Imaging. 2025 Jun 6. doi: 10.1007/s00259-025-07392-y.

DOI:10.1007/s00259-025-07392-y
PMID:40478512
Abstract
摘要

相似文献

1
Recurrent pulmonary lymphangitis carcinomatosis detected on Lu-PSMA-617 post-therapy scan in mCRPC with negative PSMA PET and HRCT.在PSMA PET和HRCT均为阴性的mCRPC患者中，经Lu-PSMA-617治疗后扫描发现复发性肺淋巴管癌病。
Eur J Nucl Med Mol Imaging. 2025 Jun 6. doi: 10.1007/s00259-025-07392-y.
2
Therapeutic efficacy, prognostic variables and clinical outcome of Lu-PSMA-617 PRLT in progressive mCRPC following multiple lines of treatment: prognostic implications of high FDG uptake on dual tracer PET-CT vis-à-vis Gleason score in such cohort.多线治疗后进展性 mCRPC 中 Lu-PSMA-617 PRLT 的治疗效果、预后变量和临床结果：在该队列中，双示踪剂 PET-CT 上高 FDG 摄取与 Gleason 评分相比的预后意义。
Br J Radiol. 2019 Dec;92(1104):20190380. doi: 10.1259/bjr.20190380. Epub 2019 Nov 1.
3
mCRPC progression of disease after [Lu]Lu-PSMA-617 detected on [F]Choline: a case of PCa heterogeneity.在[F]胆碱检测到[Lu]Lu-PSMA-617后mCRPC疾病进展：一例前列腺癌异质性病例
Urol Case Rep. 2024 May 8;54:102750. doi: 10.1016/j.eucr.2024.102750. eCollection 2024 May.
4
Pretherapeutic PSMA PET-Derived Semiquantitative Parameters as Predictors of PSA Response in Patients with mCRPC Receiving [ Lu]Lu-PSMA-617 Radioligand Therapy.治疗前PSMA PET衍生的半定量参数作为接受[镥]镥-PSMA-617放射性配体治疗的mCRPC患者PSA反应的预测指标。
Indian J Radiol Imaging. 2024 Feb 23;34(4):579-587. doi: 10.1055/s-0044-1779634. eCollection 2024 Oct.
5
Same-day post-therapy imaging with a new generation whole-body digital SPECT/CT in assessing treatment response to [Lu]Lu-PSMA-617 in metastatic castration-resistant prostate cancer.新一代全身数字 SPECT/CT 同日治疗后成像在评估转移性去势抵抗性前列腺癌中[Lu]Lu-PSMA-617 治疗反应中的应用。
Eur J Nucl Med Mol Imaging. 2024 Jul;51(9):2784-2793. doi: 10.1007/s00259-024-06718-6. Epub 2024 Apr 18.
6
Analysis of Molecular Imaging Biomarkers Derived from [F]FDG PET/CT in mCRPC: Whole-Body Total Lesion Glycolysis (TLG) Predicts Overall Survival in Patients Undergoing [Ac]Ac-PSMA-617-Augmented [Lu]Lu-PSMA-617 Radioligand Therapy.去势抵抗性前列腺癌中源自[F]FDG PET/CT的分子影像生物标志物分析：全身总病变糖酵解（TLG）预测接受[Ac]Ac-PSMA-617增强的[Lu]Lu-PSMA-617放射性配体治疗患者的总生存期
Cancers (Basel). 2024 Oct 19;16(20):3532. doi: 10.3390/cancers16203532.
7
Prognostic value of [F]FDG- and PSMA-PET in patients evaluated for [Lu]Lu-PSMA therapy of mCRPC.[F]FDG和PSMA-PET在接受[Lu]Lu-PSMA治疗评估的mCRPC患者中的预后价值。
Eur J Nucl Med Mol Imaging. 2025 Mar 21. doi: 10.1007/s00259-025-07198-y.
8
AlphaBet: Combination of Radium-223 and [ Lu]Lu-PSMA-I&T in men with metastatic castration-resistant prostate cancer (clinical trial protocol).AlphaBet：镭-223与[镥]镥-PSMA-I&T联合用于转移性去势抵抗性前列腺癌男性患者（临床试验方案）
Front Med (Lausanne). 2022 Nov 18;9:1059122. doi: 10.3389/fmed.2022.1059122. eCollection 2022.
9
Comparison of novel PSMA-targeting [Lu]Lu-P17-087 with its albumin binding derivative [Lu]Lu-P17-088 in metastatic castration-resistant prostate cancer patients: a first-in-human study.新型 PSMA 靶向配体[Lu]Lu-P17-087 与其白蛋白结合衍生物[Lu]Lu-P17-088 在转移性去势抵抗性前列腺癌患者中的比较：一项首次人体研究。
Eur J Nucl Med Mol Imaging. 2024 Jul;51(9):2794-2805. doi: 10.1007/s00259-024-06721-x. Epub 2024 Apr 25.
10
Overview of selected completed prospective studies on PSMA-targeted radioligand therapy with [177Lu]Lu-PSMA-617 in metastatic castration-resistant prostate cancer.关于[177Lu]Lu-PSMA-617靶向放射性配体疗法治疗转移性去势抵抗性前列腺癌的部分已完成前瞻性研究综述。
Rofo. 2025 Jan 22. doi: 10.1055/a-2514-4523.

本文引用的文献

1
Incidental Detection of Pulmonary Lymphangitic Carcinomatosis on F-PSMA 1007 in a Case of Prostate Cancer Without Pulmonary Symptoms.在一例无肺部症状的前列腺癌患者中，F-PSMA 1007偶然检测到肺淋巴管癌病。
Nucl Med Mol Imaging. 2025 Jun;59(3):212-213. doi: 10.1007/s13139-024-00904-y. Epub 2025 Jan 9.
2
Same-day post-therapy imaging with a new generation whole-body digital SPECT/CT in assessing treatment response to [Lu]Lu-PSMA-617 in metastatic castration-resistant prostate cancer.新一代全身数字 SPECT/CT 同日治疗后成像在评估转移性去势抵抗性前列腺癌中[Lu]Lu-PSMA-617 治疗反应中的应用。
Eur J Nucl Med Mol Imaging. 2024 Jul;51(9):2784-2793. doi: 10.1007/s00259-024-06718-6. Epub 2024 Apr 18.
3
Diffuse Pneumonitis after Lutetium-177-PSMA-617 Treatment in a Patient with Metastatic Castration-Resistant Prostate Cancer.
镥-177-PSMA-617 治疗转移性去势抵抗性前列腺癌患者后出现弥漫性细支气管炎。
BMJ Case Rep. 2024 Feb 23;17(2):e257772. doi: 10.1136/bcr-2023-257772.
4
Early response monitoring during [Lu]Lu-PSMA I&T therapy with quantitated SPECT/CT predicts overall survival of mCRPC patients: subgroup analysis of a Swiss-wide prospective registry study.Lu-PSMA I&T 治疗期间的早期反应监测通过定量 SPECT/CT 预测 mCRPC 患者的总生存期：瑞士全范围前瞻性登记研究的亚组分析。
Eur J Nucl Med Mol Imaging. 2024 Mar;51(4):1185-1193. doi: 10.1007/s00259-023-06536-2. Epub 2023 Dec 1.
5
Lu-PSMA SPECT Quantitation at 6 Weeks (Dose 2) Predicts Short Progression-Free Survival for Patients Undergoing Lu-PSMA-I&T Therapy.（剂量 2）6 周时 Lu-PSMA SPECT 定量预测 Lu-PSMA-I&T 治疗患者的短期无进展生存期。
J Nucl Med. 2023 Mar;64(3):410-415. doi: 10.2967/jnumed.122.264677. Epub 2022 Sep 8.
6
18F-PSMA-1007 Uptake in Pulmonary Lymphangitic Carcinomatosis Metastasis From Prostate Cancer.18F-PSMA-1007在前列腺癌肺淋巴管癌转移灶中的摄取情况
Clin Nucl Med. 2021 Jul 1;46(7):e355-e357. doi: 10.1097/RLU.0000000000003582.
7
Lymphangitis carcinomatosa: a literature review.癌性淋巴管炎：文献综述
J R Coll Surg Edinb. 1996 Feb;41(1):7-13.